TGTX supply chain intelligence for TG Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
TG Therapeutics, Inc. (TGTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| OBDC | Blue Owl Capital Corporation | 92% | Reciprocal relationship from OBDC graph: Reciprocal relationship from TGTX graph: the lenders party thereto and Blue Owl Capital Corporation, as administrative agent (the “Administrative Agent”), whi… |
| OBDC | Blue Owl Capital Corporation | 92% | the lenders party thereto and Blue Owl Capital Corporation, as administrative agent (the “Administrative Agent”), which amends the financing agreement |
| CERTAIN-SUBSIDIARIES-OF-THE-BORROWER | CERTAIN-SUBSIDIARIES-OF-THE-BORROWER | 90% | certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and Blue Owl Capital Corporation, as administrative agent |
| MXCT | MaxCyte, Inc. | 85% | Reciprocal relationship from MXCT graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT g… |
| DTIL | Precision BioSciences, Inc. | 72% | oduct candidates. The Company may seek significant additional financing in the future to support strategic initiatives and its ongoing and planned operations. The Company's common stock is quoted on … |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: oduct candidates. The Company may seek significant additional financing in the future to support strategic initiative… |
| FBIO | Fortress Biotech, Inc. | 72% | Reciprocal relationship from FBIO graph: r ended December 31, 2029 3,054 Year ended December 31, 2030 3,056 Other 2,058 Total operating lease liabilities 16,780 Less: present value discou… |
| FBIOP | FBIOP | 72% | Reciprocal relationship from FBIOP graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from FBIOP graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from FBIO… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NEURAXPHARM | NEURAXPHARM | 92% | License, milestone, royalty and other revenue consist primarily of recognition of consideration received under the ex-U.S. commercialization agreement (the Commercialization Agreement) with Neuraxpharm. |
| CUSTOMER-1 | CUSTOMER-1 | 90% | Three months ended March 31, 2026 Customer 1 42 % 39 % |
| CUSTOMER-2 | CUSTOMER-2 | 90% | Three months ended March 31, 2026 Customer 2 27 % 34 % |
| CUSTOMER-3 | CUSTOMER-3 | 90% | Three months ended March 31, 2026 Customer 3 20 % 16 % |
| CUSTOMER-4 | CUSTOMER-4 | 90% | Three months ended March 31, 2026 Customer 4 9 % 11 % |
| DTIL | Precision BioSciences, Inc. | 72% | arket condition is ultimately satisfied. The Company accounts for forfeitures as they occur. The Company also grants stock tracking units (STUs), which are liability-classified awards that are econom… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from DTIL g… |
| FBIO | Fortress Biotech, Inc. | 72% | Reciprocal relationship from FBIO graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from FBIO g… |
| FBIOP | FBIOP | 72% | Reciprocal relationship from FBIOP graph: 6 Year ended December 31, 2027 Year ended December 31, 2028 Year ended December 31, 2029 Other Total operating lease liabilities Less: presen… |
| HTGC | Hercules Capital, Inc. | 72% | nd approximately $ 52.3 million related to restricted stock with market conditions, expected to be recognized over a weighted-average period of 2.9 years. Milestone-based noncash compensation expense… |
| HTGC | Hercules Capital, Inc. | 72% | Reciprocal relationship from HTGC graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from HTGC g… |
| MXCT | MaxCyte, Inc. | 72% | Reciprocal relationship from MXCT graph: ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial mil… |
| NVSEF | Novartis AG | 72% | all rights under the Commercialization Agreement for a period of two years in the event of a change in control of TG. 13 Table of Contents TG-1701 (BTK inhibitor) In January 2018, we entered into… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from TGTX graph: all rights under the Commercializ… |
| OBDC | Blue Owl Capital Corporation | 72% | Reciprocal relationship from OBDC graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from TGTX graph: our only marketed product. We expec… |
| OBDC | Blue Owl Capital Corporation | 72% | our only marketed product. We expect to continue to incur significant research and development expenses, as well as significant commercialization and outsourced manufacturing expenses as we continue … |
| VNDA | Vanda Pharmaceuticals Inc. | 72% | Reciprocal relationship from VNDA graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from VNDA graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from VNDA g… |
| TG-CELL-THERAPY-INC | TG-CELL-THERAPY-INC | 62% | 0.0 million upon contract execution and a $ 12.5 million milestone payment upon the first key market commercial launch in the EU. The Company is eligible to receive up to an additional $ 492.5 millio… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TGTX-DEBT | Debt stack $745.4M | 90% | Market cache reports total debt of $745.4M. |
| TGTX-DEBT-12968 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-12-31. |
| TGTX-DEBT-12967 | Warrants outstanding: 147058 | 90% | xbrl warrant detail from xbrl 2023-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TGTX-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 368 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BIO | Bio-Rad Laboratories, Inc. | 100.00 | 2 | |
| FBIO | Fortress Biotech, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DERM | Journey Medical Corporation | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| CELU | Celularity Inc. | 100.00 | 2 | |
| ENGN | enGene Therapeutics Inc. | 100.00 | 2 | |
| IRON | Disc Medicine, Inc. | 100.00 | 2 | |
| ALEC | Alector, Inc. | 100.00 | 2 | |
| ANAB | AnaptysBio, Inc. | 100.00 | 2 | |
| CMPS | COMPASS Pathways plc | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| FBIOP | Fortress Biotech, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DB | Deutsche Bank Aktiengesellschaft | 100.00 | 2 | |
| HBIO | Harvard Bioscience, Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| ALT | Altimmune, Inc. | 100.00 | 2 | |
| BBIO | BridgeBio Pharma, Inc. | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 1 | ['customer'] |
| FISI | Financial Institutions, Inc. | 100.00 | 2 |